FDA grants accelerated approval to iberdomide with daratumumab and hyaluronidase-fihj and dexamethasone for multiple myeloma By Ogkologos - October 7, 2026 6 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the EXCALIBER-RRMM study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge Adjuvant fractionated radiotherapy significantly improves DFS in patients with atypical meningioma who have undergone complete surgical resection MOST POPULAR Telehealth Can Save People with Cancer Time, Travel, and Money February 16, 2023 Clinical Utility of ctDNA NGS for Detecting Actionable Alterations According ESCAT... September 26, 2022 New on NCI’s Websites for March 2022 March 16, 2022 News digest – naked mole-rats, junk food deals, ovarian cancer drug... July 4, 2020 Load more HOT NEWS FDA Approves Teclistamab in Combination with Daratumumab Hyaluronidase-fihj for Relapsed or... Nivolumab Plus Chemotherapy Continues to Demonstrate Long-Term Survival Benefits in Patients... High Tumour Mutation Burden Fails to Predict Response to Immune Checkpoint... Motixafortide May Improve Stem Cell Transplants for People with Multiple Myeloma
